drugset / Trial / NCT03483753

Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery

NCT03483753 ↗

Phase 2/3 Withdrawn University of Sao Paulo
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the present study is to evaluate the effect of vasopressin compared to norepinephrine on the clinical complications of patients with vasospastic shock after noncardiac surgeries.

Timeline

Start
2019-01
Primary completion
2023-10-02
Completion
2023-10-02

Outcome

Met primary endpoint

Stopped (Business): “no funding for the study”

paper 32% of the vasopressin patients and in 49% of the norepinephrine patients (unadjusted hazard ratio, 0.55; 95% CI, 0.38 to 0.80; P = 0.0014). PMID 27841822 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Norepinephrine Other / unclassified 0.1 ug/kg —
Comparator Norepinephrine Other / unclassified 1 ug/kg —
Subject Vasopressin Peptide 0.01 iu —
Subject Vasopressin Peptide 0.06 iu —

Indications

No indication recorded.